Trial
NCT03760484
Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Alberta
Collaborators
—
Condition
Clostridium Difficile
Intervention
Fidaxomicin 200 mg
Why stopped
Difficulty enrolling participants/COVID pandemic/lack of continued in-kind support from product manufacturer.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-13